Treatmybrand


a Kainjoo SA Venture
Ch. du Vernay 14a
1196 Gland
+41.21.561.34.96
info@treatmybrand.com

Support


Monday to Friday
8AM to 8PM
support@treatmybrand.com
Back

Isomorphic Labs raises $5B to advance AI-designed drugs towards clinical trials

Isomorphic Labs, spun out of DeepMind in 2021, has secured $5 billion in Series C funding to advance its AI-designed drug candidates towards clinical trials. The round was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz joining existing backers including Alphabet’s venture arms and the U.K. Sovereign AI Fund.

The company uses simulation AI models to design drugs, building on DeepMind’s AlphaFold protein-folding breakthrough. Isomorphic Labs reports positive preclinical results in oncology and immunology, and has already signed deals with Eli Lilly, Novartis, and Johnson & Johnson. The new funds will support further development of its drug-design engine and expansion into more therapeutic areas.

This is the first major fundraise since Demis Hassabis shifted his focus from DeepMind to lead Isomorphic Labs, following his Nobel Prize-winning work on AlphaFold. The company did not disclose its new valuation, but Bloomberg reported it was seeking funds at a $50 billion valuation.

For pharma and biotech executives, this scale of investment in AI-driven discovery confirms the sector’s direction. The next milestone will be clinical trial results and further collaborations with established pharmaceutical companies.

TechCrunch
TechCrunch